Patents
Literature
4 results about "Chronic lymphocytic leukemia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A type of cancer that begins in the lymphocytes of bone marrow and extends into the blood.
Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide
PCT designated stageWO2026006456A8Organic active ingredientsPharmaceutical delivery mechanismCD20Chronic lymphocytic leukemia
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.
Owner:GENENTECH INC +2
An irak4 kinase inhibitor
The application discloses a novel IRAK4 inhibitor compound shown in formula (I) and use of the compound for preventing or treating IRAK4-mediated diseases, which include but are not limited to rheumatoid arthritis, lupus erythematosus and other autoimmune diseases, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, relapsed non-Hodgkin's lymphoma and other lymphomas.
Owner:SHANGHAI SINOV BIOPHARMACEUTICAL CO LTD
Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
This disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.
Owner:INCYTE CORP
Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
PendingUS20260176355A1Organic active ingredientsPharmaceutical delivery mechanismAntiendomysial antibodiesPharmacy medicine
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.
Owner:INCYTE CORP